MIL 98
Alternative Names: MIL-98Latest Information Update: 01 Apr 2022
At a glance
- Originator Beijing Mabworks Biotech
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Lymphoma; Malignant melanoma; Solid tumours
Most Recent Events
- 18 Mar 2022 Beijing Mabworks Biotech plans to file an IND application for Solid tumours in 2022 (Beijing Mabworks Biotech pipeline, March 2022)
- 18 Mar 2022 Preclinical trials in Lymphoma in China (Parenteral), before March 2022 (Beijing Mabworks Biotech pipeline, March 2022)
- 18 Mar 2022 Preclinical trials in Malignant melanoma in China (Parenteral), before March 2022 (Beijing Mabworks Biotech pipeline, March 2022)